Evolution of Plasmodium vivax and resistance patterns for infection based on Duffy genotype and phenotype

• Published in: Le infezioni in medicina Vol. 31; no. 3; pp. 350 - 358
• Main Authors: Picón-Jaimes, Yelson Alejandro, Lozada-Martinez, Ivan David, Forero Buelvas, María Camila, Ardila Sarmiento, Andrés Felipe, Serrano Baez, Gustavo Adolfo, Nazareno Erazo, Deilly Yohana, Cuastumal Martínez, José Daniel, Ruiz-Gutierrez, Franklin Kevin, Carreño Barrera, Victor Daniel
• Format: Journal Article
• Language: English
• Published: InfezMed 2023
• Subjects: Reviews
• DOI: 10.53854/liim-3103-8
• EISSN: 2532-8689
• ISSN: 1124-9390

The Duffy protein, a transmembrane molecule, acts as a receptor for various chemokines and facilitates binding between reticulocytes and the
Plasmodium
Duffy antigen binding protein. Duffy expression is associated with the Duffy chemokine receptor antigen genotype on chromosome 1 and exhibits variation across different geographic regions. Traditionally, the Duffy negative genotype and phenotype have been described to confer a certain level of protection against infection and symptom development. However, recent data suggest a shift in this behavior, with significantly higher prevalence observed in individuals with Duffy negative genotype or phenotype. Given that malaria is an endemic vector-borne disease in regions of Asia, Africa, and Latin America, posing a substantial global burden of disease and prioritizing public and global health, identifying evolutionary changes in infection and resistance patterns holds great importance for the design of strategies and reevaluation of conventional interventions. Hence, the aim of this review was to analyze the evolution of
Plasmodium vivax
and infection resistance patterns based on Duffy genotype and phenotype. The distribution of genotypes, phenotypes, and polymorphisms of
P. vivax
ligands and erythrocyte receptors varies geographically, notably resistance patterns of this microorganism in individuals with Duffy negative genotype and phenotype have significantly changed compared to studies conducted 30 years ago. The prevalence of vivax malaria in individuals with a Duffy negative status can reach up to 100%. Consequently, prioritizing research on this topic is essential for public health.